Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 10 recruiting now early-phase tilt

Peripheral Vascular Diseases: early-phase trial registry

10 of 20 indexed Peripheral Vascular Diseases trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #848 of 28,707 conditions by registered trial count.

20 US clinical trials · 10 currently recruiting · #848 of 28,707 conditions by registered trial count

Peripheral Vascular Diseases: 20 US clinical trials tracked, 10 recruiting.

Peripheral Vascular Diseases is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Northwestern University, running 4 of these trials.

Enrollment posture brief

Registry condition peripheral-vascular-diseases

OPEN 10 | RECR 50% | LATE 2 | EARLY 6 | RANK #848 | SPON 4

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Advanced or Metastatic Solid55%ALS50%Peripheral Vascular Dise (th…50%Abdominal Pain25%Acute Myocardial Infarction25%
Open-enrollment share among volume-matched conditions near Peripheral Vascular Diseases

Peripheral Vascular Diseases lists 10 open slots (50% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Peripheral Vascular Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Peripheral Vascular Diseases is recruiting above its size-band peers.

    10 of 20 indexed trials (50%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Peripheral Vascular Diseases research.

    Northwestern University accounts for 4 of 20 trials (20%). 14 distinct sponsors appear on at least one study for this condition label.

  3. Typical Peripheral Vascular Diseases enrolment sits around 200 participants.

    Median target enrolment is 200 among the 20 trials that report a genuine target (sentinel values excluded). 5 of those (25%) plan for fewer than 100 participants.

  4. Peripheral Vascular Diseases research is mostly interventional.

    16 interventional and 4 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 23Phase 31Phase 41

Open and recent trials

20 total, page 1 of 1

RECRUITING 5,000 participants

Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature

Boston Scientific Corporation

NCT04674969

RECRUITING NA 720 participants

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 1

Virginia Commonwealth University

NCT04916327

RECRUITING NA 400 participants

Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy

Brigham and Women's Hospital

NCT06300450

RECRUITING NA 360 participants

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 2

Virginia Commonwealth University

NCT04922762

RECRUITING NA 240 participants

Examining the Impact of Exercise Training on Vascular Dysfunction in Individuals With Mental Health Disorders - Study 3

Virginia Commonwealth University

NCT04916340

RECRUITING Phase 3 210 participants

SMART Exercise for PAD

Northwestern University

NCT06032065

RECRUITING 175 participants

MRI Guided Management of Occlusive Peripheral Arterial Disease

The Methodist Hospital Research Institute

NCT06782100

RECRUITING Phase 2 34 participants

Fisetin to Reduce Senescence and Mobility Impairment in PAD

Northwestern University

NCT06399809

RECRUITING Early Phase 1 20 participants

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

University of Nebraska

NCT06319339

RECRUITING Phase 1 10 participants

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Louis Messina

NCT04800692

ACTIVE NOT RECRUITING Phase 2 720 participants

Virtual Diabetes Group Visits Across Health Systems

University of Chicago

NCT06094491

COMPLETED 519 participants

Magnetic Resonance Imaging to Identify Characteristics of Plaque Build-Up in People With Peripheral Arterial Disease

Northwestern University

NCT00520312

COMPLETED NA 355 participants

Reducing Risk Factors in Peripheral Arterial Disease

Northwestern University

NCT00217919

COMPLETED NA 200 participants

GORE-TEX PROPATEN Vascular Graft Study

W.L.Gore & Associates

NCT00205790

COMPLETED NA 119 participants

GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)

W.L.Gore & Associates

NCT00541307

COMPLETED NA 116 participants

Implementation of Telemedicine for Patient With Lower Extremity Wounds

University of California, Davis

NCT04440839

COMPLETED 100 participants

Distributed Registry

Stanford University

NCT03898570

COMPLETED Phase 2 100 participants

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

ARCA Biopharma

NCT00073554

COMPLETED Phase 4 30 participants

Peripheral Nerve Blocks for Above-the-knee Amputations

University of Florida

NCT03404180

COMPLETED Phase 1 9 participants

Natural Vascular Scaffold (NVS) Therapy for Treatment of Atherosclerotic Lesions (Activate I)

Alucent Biomedical

NCT04188262

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Peripheral Vascular Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Obturator nerve blocks Procedure
1 trials
Lateral femoral cutaneous nerve blocks Procedure
1 trials
Intravenous Sedatives Drug
1 trials
Peripheral nerve block Procedure
1 trials
Health-Counselor Mediated Telephone Counseling Intervention Behavioral
1 trials
Alfimeprase Drug
1 trials
Telemedicine specialty consultation Other
1 trials
Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface Device
1 trials

US sites by state

Facility locations filed on Peripheral Vascular Diseases trials. A trial with sites in several states counts in each.

Illinois 7 trials
Massachusetts 4 trials
California 4 trials
Virginia 3 trials
Florida 3 trials
Texas 2 trials
Tennessee 2 trials
Ohio 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Peripheral Vascular Diseases page

20 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 10 Peripheral Vascular Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Northwestern University sponsors the most Peripheral Vascular Diseases trials on record, review their full trial history before evaluating a specific study. See Northwestern University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Peripheral Vascular Diseases condition card totals 20 registered trials; most-linked intervention Obturator nerve blocks; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.